...from Mass Eye and Ear Last week, Biogen Inc. (NASDAQ:BIIB) gained exclusive, worldwide rights from Massachusetts Eye and Ear...
...processing factor 31 BC Staff Dragonfly Therapeutics Inc. Bristol Myers Squibb Co. HiberCell Inc. Biothera Pharmaceuticals Inc. Case Western Reserve University Biogen Inc. Massachusetts Eye and Ear LMY-920 Luminary...

...meek B cell vaccines,” said Luk Vandenberghe, director of the Grousbeck Gene Therapy Center at Massachusetts Eye and Ear...
...Capacity for COVID-19 Vaccines” ). Targets SARS-CoV-2 S - SARS-CoV-2 spike protein Karen Tkach Tuzman, Associate Editor Massachusetts Eye and Ear Massachusetts...

...of manufacturers in COVID-19 countermeasures. The AAVCOVID vaccine program, spearheaded by Massachusetts General Hospital and Massachusetts Eye and Ear...

...see “Mapping the Path to Gene Therapy 2.0” ). Vandenberghe is an associate professor at Massachusetts Eye and Ear...
...Waltham, Mass. Technology: Rational AAV vector design platform Origin of technology: Lonza Group Inc. and Massachusetts Eye and Ear...

...of Editas Medicine Inc. (NASDAQ:EDIT) and serves on the boards of Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG), Massachusetts Eye and Ear...

...retinal diseases. The first program will deliver RPGRIP1 via Anc80, a vector system developed by Massachusetts Eye and Ear...

...The Boston-based non-profit was founded in 2016 by biotech entrepreneur Scott Dorfman and two non-profits: Massachusetts Eye and Ear...
...for discount vector manufacturing and reserved manufacturing slots. Both Lonza and Odylia have rights from Massachusetts Eye and Ear...
...Molecular Therapeutics Inc., Emeryville, Calif. Indiana University, Indianapolis, Ind. Lonza Group Ltd. (SIX:LONN), Basel, Switzerland Massachusetts Eye and Ear...

...license to a vector platform to develop gene therapies for hearing and balance disorders from Massachusetts Eye and Ear...

...in Akouos' $7.5 million seed round in December (see "Akouos Licenses Gene Therapy Tech From Massachusetts Eye and Ear"...
...license to a vector platform to develop gene therapies for hearing and balance disorders from Massachusetts Eye and Ear...
...Smith, former CEO of Cochlear Ltd. (ASX:COH). Akouos Inc., Boston, Mass. Elizabeth S. Eaton Akouos Inc. Harvard Medical School Massachusetts Eye and Ear...

...license to a vector platform to develop gene therapies for hearing and balance disorders from Massachusetts Eye and Ear...
...candidate in 2020. In a pair of papers published last year in Nature Biotechnology , Massachusetts Eye and Ear...